The Medicines and Healthcare Products Regulatory Agency (MHRA) has released its Annual Report and Accounts, recording the Agency’s progress in the last year.
The Report explains the MHRA’s progress against its Business Plan 2020-21 which was organised around five strategic goals:
- Patients, Public and Health Service – to ensure information and advice is available to enable well-informed decisions by patients and healthcare professionals, by engaging proactively with the public, patients, health services, and health care professionals
- Innovation and Regulatory Science – to support the development of better, safer healthcare products for patients, underpinned by innovation, scientific evidence, and technology
- Lifecycle and Safety Management – to improve proportionate decision-making in the interests of patients
- Data and Analytics – to enhance access to data, data services, and evidence-based data analysis to underpin MHRA’s regulatory and science processes
- Governance and Partnerships – to develop reinforced governance, delivery capacity and external partnership working
This year’s MHRA highlights included:
We played a key role in tackling coronavirus, working with others across the health system and with industry to support the UK’s response, demonstrating our agility by quickly re-prioritising our work to meet the unprecedented demand…
Our Innovation Office campaign promoted the expert regulatory guidance we provide to support organisations to develop innovative medicines, medical devices or novel manufacturing processes…
“Driving early access to medicines
Our Promising Innovative Medicine (PIM) scheme has supported a diverse range of treatments including; five positive scientific opinions have been issued for amyloid cardiomyopathy, lung cancer, B-cell lymphoma, renal cancer and multiple myeloma treatments.”
Read the full Report on the MHRA website.